Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

4.105 -0.085 (-2.03%)
Streaming Delayed Price Updated: 2:38 PM EDT, May 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,283,801
Open 4.190
Bid (Size) 4.100 (6)
Ask (Size) 4.110 (6)
Prev. Close 4.190
Today's Range 3.900 - 4.250
52wk Range 3.420 - 20.70
Shares Outstanding 36,130,121
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug
Analyst Selvaraju downgrades UroGen after FDA panel setback dims approval prospects for key bladder cancer drug UGN-102. 
Via Benzinga
Exposures Product Safety
Kaplan Fox Reminds Investors of UroGen Pharma Ltd. (URGN) to an Investigation of Potential Securities Law Violations
Via NewMediaWire
Exposures Product Safety

Performance

YTD
-61.6%
-61.6%
1 Month
-63.5%
-63.5%
3 Month
-57.9%
-57.9%
6 Month
-67.1%
-67.1%
1 Year
-69.8%
-69.8%

More News

Read More
Kaplan Fox Reminds Investors of UroGen Pharma Ltd. (URGN) to an Investigation of Potential Securities Law Violations
Via TheNewswire.com
Exposures Product Safety
Kaplan Fox is Investigating Potential Securities Law Violations against UroGen Pharma Ltd. (URGN)
Via NewMediaWire
Exposures Product Safety
Kaplan Fox is Investigating Potential Securities Law Violations against UroGen Pharma Ltd. (URGN)
Via TheNewswire.com
Exposures Product Safety
Earnings Scheduled For May 12, 2025
Via Benzinga
A Look at UroGen Pharma's Upcoming Earnings Report
Via Benzinga
Kaplan Fox Announces an Investigation Into UroGen Pharma Ltd. (URGN) for Potential Securities Law Violations
Via NewMediaWire
Exposures Product Safety
Kaplan Fox Announces an Investigation Into UroGen Pharma Ltd. (URGN) for Potential Securities Law Violations
Via TheNewswire.com
Exposures Product Safety
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd.  - URGN
From Pomerantz LLP
Via GlobeNewswire
This Guidewire Software Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Via Benzinga
What's Going On With UroGen Pharma Stock Wednesday?
Via Benzinga
UroGen Stock Slumps After FDA Advisory Committee Flag Concerns On Its Investigational Drug: But Retail’s Unruffled
Via Stocktwits
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
From UroGen Pharma Ltd.
Via Business Wire
Securities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced – Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
UroGen Pharma Ltd. (URGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Securities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Via Chartmill
Top stock movements in today's session.
Via Chartmill
The market is filled with gapping stocks in Friday's session.
Via Chartmill
UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update
From UroGen Pharma Ltd.
Via Business Wire
UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen
Via Business Wire
UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates
Via Benzinga
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday
Via Benzinga

Frequently Asked Questions

Is UroGen Pharma Ltd. - Ordinary Shares publicly traded?
Yes, UroGen Pharma Ltd. - Ordinary Shares is publicly traded.
What exchange does UroGen Pharma Ltd. - Ordinary Shares trade on?
UroGen Pharma Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for UroGen Pharma Ltd. - Ordinary Shares?
The ticker symbol for UroGen Pharma Ltd. - Ordinary Shares is URGN on the Nasdaq Stock Market
What is the current price of UroGen Pharma Ltd. - Ordinary Shares?
The current price of UroGen Pharma Ltd. - Ordinary Shares is 4.105
When was UroGen Pharma Ltd. - Ordinary Shares last traded?
The last trade of UroGen Pharma Ltd. - Ordinary Shares was at 05/27/25 02:38 PM ET
What is the market capitalization of UroGen Pharma Ltd. - Ordinary Shares?
The market capitalization of UroGen Pharma Ltd. - Ordinary Shares is 148.31M
How many shares of UroGen Pharma Ltd. - Ordinary Shares are outstanding?
UroGen Pharma Ltd. - Ordinary Shares has 148M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.